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PreviewsTelling the liver (not) to make bile acids:
a new voice from the gut?
The maintenance of adequate amounts of bile acids in the liver, biliary tract, and intestine requires a finely tuned control
of their synthesis. A paper in this issue of Cell Metabolism by Inagaki et al. (2005) indicates that sensing of the levels of
bile acids in the intestine may trigger the secretion of a hormone which regulates bile acid production in the liver.Bile acids, made from cholesterol in the
liver, are detergent molecules which are
secreted as conjugates into hepatic bile,
stored in the gallbladder, and propelled
into the duodenum as part of the integ-
rated physiological response to a meal.
After contributing to the absorption of
fat, cholesterol, and fat-soluble vitamins
in the upper small intestine, most bile
acids are actively reabsorbed in the ter-
minal ileum and returned to the liver via
the portal vein. The nonabsorbed frac-
tion is excreted in the feces and needs
to be replaced by de novo synthesis in
order to maintain an intact bile acid pool
in the enterohepatic circulation. This flux
of bile acids can be influenced by sev-
eral factors, such as gallbladder func-
tion and intestinal motility, but also by
changes in diet and the intestinal micro-
flora which may modify the individual
bile acid molecules. Since stimulation of
bile acid synthesis elicits favorable com-
pensatory responses, including mobili-
zation of cholesterol by the liver, thereby
decreasing the plasma levels of athero-
genic lipoproteins, the notion of manipu-
lating the normal enterohepatic circu-
lation for therapy has been revitalized
(Angelin et al., 1999).
The concept of bile circulation dates
back to the seventeenth century, shortly
after Harvey described the paradigm for
blood. Following on from key results ob-
tained using animals in the late-nine-
teenth century (Reuben, 2005), the dy-
namics of the enterohepatic circulation
have been under constant investigation.
However, despite the molecular elucida-
tion of important gate-keeping struc-
tures (Figure 1) in the last few years, our
understanding of how the body regu-
lates the major pathway of cholesterol
degradation is still incomplete. Bile acids
are believed to exert end-product feed-
back inhibition of their own synthesis at
the completion of their cycle. The unique-
ness of this regulation is obvious, since
the end-product has to pass through a
number of organs before reaching its final
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NCELL METABOLISM : OCTOBER 2005 · VOL. 2igure 1. Enterohepatic circulation of bile acids
holesterol, derived from circulating lipoproteins or from de novo synthesis in the liver, is converted to bile
cids through chemical modifications initiated by 7α-hydroxylation. After conjugation to taurine or glycine,
ile acids are actively secreted from the hepatocyte, together with free cholesterol and phospholipids, and
re retained in the gallbladder during fasting. In response to a meal, cholecystokinin is released from the gut,
esulting in the release of concentrated bile to the duodenum, where the detergent bile acids promote the
bsorption of dietary fat. Passive uptake of some bile acids occurs along the small intestine, but the major
raction is taken up by active transport in the terminal ileum. Bile acids are theniu transported in the portal
ein back to the liver, where they are actively taken up in hepatocytes and resecreted into bile, thereby
ompleting their enterohepatic circulation. The amount of bile acids lost in the feces is compensated for by
e novo synthesis of bile acids by the liver, resulting in the maintenance of an intact pool of bile acids in the
ody. The sensing of the amount of circulating bile acids can be achieved by the interaction of returning bile
cids in the hepatocyte but may also be the result of bile-acid-controlled release of FGF15 from the en-
erocyte.
bbreviations: BSEP, bile salt export pump; CYP7A1, cholesterol 7α hydroxylase; FGF, fibroblast growth
actor; FGFR, fibroblast growth factor receptor; FXR, farnesoid X receptor; HMG CoAR, 3-hydroxy-3-methyl-
lutaryl CoA reductase; IBABP, ileal bile acid binding protein; IBAT, ileal bile acid transporter; JNK, c-Jun
H2-terminal kinases; LDL-R, low-density lipoprotein receptor; LP, lipoproteins; NTCP, sodium taurocholate
otransporting polypeptide; OST, organic solute transporter; SHP, short heterodimer partner; * indicates struc-
ures directly regulated by FXR.
igure created by Thomas Lundåsen, Center for Nutrition and Toxicology, Department of Biosciences at
ovum, Sweden.· COPYRIGHT © 2005 ELSEVIER INC. 209
P R E V I E W Spoint of metabolic control in this pathway.
The proposal of a new intestinal signaling
mechanism which may contribute to the
maintenance of an adequate bile acid
pool by Inagaki et al. (2005) provides a
new thrust to the field.
The major pathway of bile acid bio-
synthesis is controlled by the activity of
the microsomal enzyme cholesterol 7α
hydroxylase (CYP7A1; Chiang, 2004).
The transcriptional control of this gene
is complex and still not fully understood.
Bile acids activate the nuclear receptor
farnesoid X receptor (FXR) in the liver,
which indirectly results in the repression
of Cyp7a1 transcription by the orphan
nuclear receptor small heterodimer part-
ner (SHP) partnered to the liver receptor
homolog-1 (LRH-1). FXR/SHP-indepen-
dent regulators of CYP7A1 expression,
such as PPAR-α and pregnane X recep-
tor have also been documented. In addi-
tion, in rodents—but not in humans—the
transcription of Cyp7a1 is stimulated by
cholesterol metabolites via the liver X re-
ceptor (LXR). Recently, the fibroblast
growth factor FGF19, which is under the
control of FXR, through its interaction
with its receptor FGFR4, has been shown
to downregulate CYP7A1 (Holt et al.,
2003, Yu et al., 2000, 2005). Besides
Cyp7a1, many of the genes modulating
the dynamics of enterohepatic circula-
tion of bile acids are also FXR regulated,
indicating the importance of controlling
their activity in response to bile acid
concentrations (Figure 1). Until now,
some of the previous observations in the
field had been difficult to reconcile. For
instance, blocking the intestinal flow of
bile acids by ligation of the bile duct
increases CYP7A1 expression and ac-
tivity, despite resulting in high concen-
trations of bile acids in the liver (Gustafs-
son, 1978), while reinfusion of bile acids
into the intestine rapidly downregulates
CYP7A1 expression, an effect that is not
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f210een upon intravenous or even portal
dministration of bile acids (Pandak et
l., 1991).
Inagaki et al. (2005) now show that the
ouse ortholog of FGF19, FGF15, is ex-
ressed in the small intestine, but not in
he liver, and that it is regulated by FXR
Li et al., 2005). Infusion of FGF15 re-
ults in repression of Cyp7a1 and down-
egulation of CYP7A1 activity and fecal
ile acid excretion through a mechanism
nvolving FGFR4 and, at least partly,
HP. The authors propose that the syn-
hesis and release of FGF15 in the small
ntestine functions as an enterohepatic
ignal which senses bile acid uptake
nd regulates hepatic bile acid synthesis
n an “endocrine” loop. This hypothesis
ay be helpful in explaining some of the
ontradictory observations on the regu-
ation of bile acid synthesis mentioned
bove.
Further studies will have to elucidate
he detailed mechanisms of how FGF15/
9 and FGFR4 exert their effect on
YP7A1 expression and activity and
ow this potential pathway may overlap
ith bile acid/FXR regulation. It will also
e important to characterize the cells
xpressing FGFs and the details of their
ecretion. The development of an assay
o measure circulating FGFs will be cru-
ial in understanding how FGFs may act
s intestinal hormones and whether this
henomenon is relevant in humans.
The possible presence of a gut-liver
ignaling pathway may additionally help
n the understanding of how distinct and
apid diurnal variation in bile acid syn-
hesis is controlled. Recent studies in
umans have established that bile acid
roduction displays two distinct peaks
uring daytime, with variations unrelated
o feeding (Gälman et al., 2005). It is
robable that this pattern is induced by
“clock function” from the hypothala-
us and turned off by postprandial in-
low of bile acids in the portal vein or,
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Dlternatively, by an inflow of gut-derived
GF. The potential role of intestinal sig-
aling to the liver by FGF (and other
olecules) has added a new promising
imension to the ancient concept of en-
erohepatic circulation of bile.
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